• PSY54 DEVELOPMENT OF AN OPIOID ROTATION MODEL

    May 1, 2008, 00:00

  • PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT

    May 1, 2008, 00:00

  • DU3 CALIFORNIA WILDFIRES ANDTHEIR IMPACT ON MEDICATION ACQUISITION

    May 1, 2008, 00:00

  • PCN11 A BUDGET IMPACT ANALYSIS OF IXABEPILONE IN TREATING METASTATIC CANCER PATIENTS

    May 1, 2008, 00:00

  • PMS43 CHARACTERISTICS OF PHARMACEUTICS HAVING NO ALTERNATIVES

    May 1, 2008, 00:00

  • PND21 COST-UTILITY OF PRAMIPEXOL COMPARED WITH L-DOPA/CARBIDOPA INTHE TREATMENT OF PARKINSONS DISEASE IN MEXICO

    May 1, 2008, 00:00

  • Time and Expected Value of Sample Information Wait for No Patient

    May 1, 2008, 00:00

  • PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDINGTO NATIONAL LIPID TREATMENT GUIDELINES

    May 1, 2008, 00:00

  • PCN22 IS CAPECITABINE A COST-EFFECTIVE ADJUVANT TREATMENT OF STAGE III COLON CANCER IN ONTARIO?

    May 1, 2008, 00:00

  • PMH70 AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC

    May 1, 2008, 00:00

  • PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE 65 YEARS)

    May 1, 2008, 00:00

  • PCN45 RESOURCE UTILIZATION AND COST ESTIMATION OF ADVERSE EVENTS OF NON-SMALL CELL LUNG CANCER TREATMENT IN MEXICAN PATIENTS. RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • PMH34 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- ESTIMATING THE MAXIMUM ALLOWABLE COST OF PSYCHOSOCIAL INTERVENTIONS IN THE UNITED STATES, GERMANY. THE NETHERLANDS, SWEDEN, AND THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PDB13 PREDICTING INPATIENT HOSPITALIZATION RISKS FOR MEDICAID DIABETES PATIENTS

    May 1, 2008, 00:00

  • PSY28 A SYSTEMATIC REVIEW OF LOW BACK PAIN COST OF ILLNESS STUDIES IN THE UNITED STATES AND INTERNATIONALLY

    May 1, 2008, 00:00

  • PMH2 BENCHMARKING SCHIZOPHRENIA WITH A FOCUS ON PHARMACOTHERAPYAND METABOLIC SYNDROME

    May 1, 2008, 00:00

  • PSS1 CO-MORBIDITIES INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00

  • PDB8 DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON OUTCOMES IN THE HOSPITAL SETTING

    May 1, 2008, 00:00

  • PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE- POPULATION-BASED NATURAL EXPERIMENT

    May 1, 2008, 00:00

  • PMH11 ASSESSING THE REPORTING AND SCIENTIFIC QUALITY OF META-ANALYTIC RESEARCH SYNTHESISING RANDOMIZED CONTROLLED TRIALS FOR ANXIETY DISORDER TREATMENTS

    May 1, 2008, 00:00

  • PMC13 USE OF POTENTIALLY INAPPROPRIATE PSYCHOACTIVE MEDICATIONS AND FALLS IN U.S. NURSING HOME RESIDENTS

    May 1, 2008, 00:00

  • PCV50 UP-TITRATION OF STATIN THERAPY TO MEET CANADIAN TARGET LIPID GOALS- ECONOMIC IMPACT OFTITRATION ASSOCIATED WITH COMPARATIVE EFFICACY OF ROSUVASTATIN, ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN

    May 1, 2008, 00:00

  • PIN18 THE IMPACT OF PEDIATRIC ADVERSE EVENTS ON THE COST-EFFECTIVENESS OF OSELTAMIVIR

    May 1, 2008, 00:00

  • PUK10 ECONOMIC EVALUATION OF POLYCLONAL ANTIBODIES FOR THE MANAGEMENT OF HIGH RISK PATIENTS WITH ACUTE REJECTION IN RENAL TRANSPLANTATION AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2008, 00:00

  • PMS10 THE COST-EFFECTIVENESS OF ABATACEPT VERSUS RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PERSPECTIVE OF THE CANADIAN PUBLICLY FUNDED HEALTH CARE SYSTEM

    May 1, 2008, 00:00

  • PUK3 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT

    May 1, 2008, 00:00

  • PRS29 PATIENT, CAREGIVER, AND PHYSICIAN PERCEPTIONS OF MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE- FINDINGS FROM QUALITATIVE RESEARCH

    May 1, 2008, 00:00

  • PMS13 COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PND4 TRENDS AMONG HOSPITALIZED CYSTIC FIBROSIS PATIENTS

    May 1, 2008, 00:00

  • Cost-Utility Analysis of Rimonabant in the Treatment of Obesity

    May 1, 2008, 00:00

  • PCV47 MEDICARE OUTLIER PAYMENTS FOR CORONARY ARTERY BYPASS GRAFTING

    May 1, 2008, 00:00

  • OM1 VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSETHEORY- APPLICATION OF KERNEL REGRESSION

    May 1, 2008, 00:00

  • PMS17 LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES BASED ON US NATIONAL SURVEYS

    May 1, 2008, 00:00

  • PSY14 ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO HAVE RECEIVED ONE PRIOR THERAPY

    May 1, 2008, 00:00

  • PGI20 PARTIAL RESPONDERS TO PPI TREATMENT; HOW DO THEY DIFFER FROM OTHER GERD PATIENTS IN TERMS OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILISATION?-A DATABASE ANALYSIS

    May 1, 2008, 00:00

  • PMH17 METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION

    May 1, 2008, 00:00

  • PHP75 SATISFACTION WITH MEDICATION- PRELIMINARY RESULTS FROM A NOVEL PATIENT REGISTRYTRACKING SATISFACTION WITH DIFFERENT CHRONIC MEDICATIONS

    May 1, 2008, 00:00

  • PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PMS46 TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY- A CRITICAL EVALUATION

    May 1, 2008, 00:00

  • PCN63 RACIAL DIFFERENCES IN MEDICATION ADHERENCE TO ADJUVANT HORMONAL THERAPY IN MEDICAID ENROLLED WOMEN WITH PRIMARY BREAST CANCER- A COMPARISON USING TWO ESTIMATION METHODOLOGIES

    May 1, 2008, 00:00

  • PMC16 CREATING NATIONAL WEIGHTS FOR A LARGE-SCALE, PATIENT LONGITUDINAL DATABASE

    May 1, 2008, 00:00

  • PMC36 THE USE OF A MOBILE PHONE FOR ASSESSING MOOD AND PERFORMANCE IN EVERYDAY LIFE

    May 1, 2008, 00:00

  • PCN53 THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE-A LITERATURE-BASED ECONOMIC ANALYSIS

    May 1, 2008, 00:00

  • PGI17 ADHERENCE TO INFLIXIMAB MAINTENANCE THERAPY AND ITS IMPACT ON HOSPITALIZATION OF PATIENTS WITH CROHNS DISEASE

    May 1, 2008, 00:00

  • DU4 PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • PCV96 THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS

    May 1, 2008, 00:00

  • PHP31 DRUG PROXIES FOR IDENTIFYING SPECIFIC DIAGNOSES IN MEDICARE PART D

    May 1, 2008, 00:00

  • PDB49 INFLUENCE OF FAMILY STRUCTURE ON EMERGENCY ROOM UTILIZATION OF DIABETIC MOTHERS

    May 1, 2008, 00:00

  • PSY30 EVALUATION OF COST AND OUTCOMES OF WEIGHT CONTROL PROGRAM IN A REGIONAL HOSPITAL AT SOUTHERNTAIWAN

    May 1, 2008, 00:00

  • PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO

    May 1, 2008, 00:00

  • PM1 RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PMH14 DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES- FINDINGS FROM A CLAIMS DATABASE

    May 1, 2008, 00:00

  • PCV89 PRE AND POST STROKE STATIN USE AND ASSOCIATED HEALTH CARE COSTS AMONG ELDERLY STROKE SURVIVORS

    May 1, 2008, 00:00

  • PGI18 LINGUISTIC VALIDATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) IN 35 LANGUAGES

    May 1, 2008, 00:00

  • PHP78 STABILITY OF PHYSICIAN PERFORMANCE ON PAY-FOR-PERFORMANCE PROCESS MEASURES OVERTIME- EFFECT OF PATIENT DENOMINATOR THRESHOLDS

    May 1, 2008, 00:00

  • DB4 RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY

    May 1, 2008, 00:00

  • PIH3 HOSPITALIZATIONS AND MORTALITY ASSOCIATED WITH INCIDENT POTENTIALLY INAPPROPRIATE MEDICATIONS USE AMONG ELDERLY INDIANA MEDICAID BENEFICIARIES RESIDING IN NURSING HOMES

    May 1, 2008, 00:00

  • PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY

    May 1, 2008, 00:00

  • PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN

    May 1, 2008, 00:00

  • PMH83 USING RETAIL PHARMACY PRESCRIPTION DATATO INVESTIGATE THE SEASONALITY OF ADHDTREATMENT- JANUARY 2003-OCTOBER 2007

    May 1, 2008, 00:00

  • PMS24 RESOURCE UTILIZATION AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA

    May 1, 2008, 00:00

  • PIH27 GENERIC SUBSTITUTION OF WARFARIN AMONG THE ELDERLY- AN EXAMINATION OF HOSPITAL AND EMERGENCY ROOM USE

    May 1, 2008, 00:00

  • PCV88 OLD HABITS DIE HARD- A NATIONWIDE UTILIZATION STUDY OF CALCIUM CHANNEL BLOCKERS IN TAIWAN

    May 1, 2008, 00:00

  • PMS44 PRESCRIPTION TREATMENT PATTERNS IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN

    May 1, 2008, 00:00

  • PMS29 BAYESIAN COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ANKYLOSING SPONDYLITIS

    May 1, 2008, 00:00

  • PMC49 TRANSLATING HETEROGENEITY BIAS FROM HEALTH STATUS IN OUTCOMES STUDIES-USING LATENT CLASS CLUSTER ANALYSIS AND LONGITUDINAL DATA

    May 1, 2008, 00:00

  • PCV104 RELATIONSHIP BETWEEN QUALITY OF CARE AND EXCESSIVE COST FOR MEDICARE PATIENTS UNDERGOING LOWER EXTREMITY BYPASS SURGERY

    May 1, 2008, 00:00

  • PHP57 FACTOR ANALYSIS OF PHARMACISTS PERCEIVED BARRIERS TO PROVISION OF MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) IN WEST VIRGINIA

    May 1, 2008, 00:00

  • PUK14 INPATIENT COSTS AND CLINICAL OUTCOMES OF S. AUREUS BLOODSTREAM AND NON-BLOODSTREAM INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE- FINDINGS FROM A MULTI-CENTER TRIAL

    May 1, 2008, 00:00

  • PCV10 EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL

    May 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CANADA

    May 1, 2008, 00:00

  • PRS37 CONCURRENT ASTHMA CONTROLLER MEDICATION POSSESSION PROFILES IN AN ADULT MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PUK16 COMPARATIVE ECONOMIC EVALUATION OF DUTASTERIDE VERSUS FINASTERIDE FOR MEDICARE-AGED MEN WITH BENIGN PROSTATIC HYPERPLASIA

    May 1, 2008, 00:00

  • PSS6 COST-EFFECTIVENESS OF INTERMITTENT VS. CONTINUOUS ANTI-TNF ALPHA THERAPY IN PLAQUE PSORIASIS

    May 1, 2008, 00:00

  • PMC39 A COMPREHENSIVE PARADIGM TO ESTIMATE MINIMAL CLINICALLY IMPORTANT DIFFERENCES (MCID)

    May 1, 2008, 00:00

  • PMH37 UNITED KINGDOM COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA- DIABETES AND CORONARY HEART DISEASE RISK PROJECTIONS (STAR STUDY)

    May 1, 2008, 00:00

  • PHC2 A COMPARISON OF COSTS ASSOCIATED WITH SPINAL SURGERIES BY CHOICE OF FIBRIN SEALANT

    May 1, 2008, 00:00

  • PRS23 PARTICIPANTS EXPERIENCE OF ASTHMA- RESULTS FROM A FOCUS GROUP STUDY

    May 1, 2008, 00:00

  • PMS38 ESTIMATING WORK PRODUCTIVITY- EFFECTS OFTRAMADOL EXTENDED-RELEASE TREATMENT

    May 1, 2008, 00:00

  • PHP70 PHYSICIANS KNOWLEDGE OF LABELED DRUG INDICATIONS AND ATTITUDES REGARDING OFF-LABEL USE- RESULTS OF A NATIONAL SURVEY OF GENERAL INTERNISTS AND PSYCHIATRISTS

    May 1, 2008, 00:00

  • PCV29 A COST-EFFECTIVENESS ANALYSIS OF TREATMENT TO LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL GOAL IN HIGH-RISK PATIENTS BASED UPON THE 2004 NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINE UPDATE

    May 1, 2008, 00:00

  • PIN28 A REALISTIC-AGE-STRUCTURED, DETERMINISTIC, COMPARTMENTAL. TRANSMISSION MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF VACCINATION AGAINST SEASONAL INFLUENZA

    May 1, 2008, 00:00

  • PCV59 THE COST AND EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR LIPID-LOWERING AND ANTIHYPERTENSIVE DRUGS

    May 1, 2008, 00:00

  • PRS27 INTERPRETING CLINICAL TRIALS RESULTS FOR THE ONSET OF EFFECT QUESTIONNAIRE- METHODS AND RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • PMC55 MATRIX MODEL FOR DETERMINING A DRUGS HEALTH ECONOMIC FOCUSTO OPTIMIZE ITS ECONOMICVIABILITY

    May 1, 2008, 00:00

  • PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS- A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE

    May 1, 2008, 00:00

  • PND39 PATIENT- AND PHYSICIAN-ASSESSED FUNCTIONAL DISABILITY IN PATIENTS TREATED WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PHC3 COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST LINE STRATEGY VERSUS BRIDGE

    May 1, 2008, 00:00

  • WH4 PROBIOTICS IN PREGNANCY-A SYSTEMATIC REVIEWAND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES

    May 1, 2008, 00:00

  • PCV94 PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • PHP45 COMMON DRUG REVIEW (CDR) RECOMMENDATIONS- DOES COST-EFFECTIVENESS MATTER?

    May 1, 2008, 00:00

  • PIH30 PRIVATE HEALTH INSURANCE VS. MEDICAID COVERAGE- DISPARITIES IN PROCESS OF CARE MEASURES

    May 1, 2008, 00:00

  • PCN32 COST-EFFECTIVENESS ANALYSIS OF AN HPV-16/18 PROPHYLACTIC CERVICAL CANCER VACCINE IN A SETTING OF EXISTING SCREENING IN PORTUGAL-RESULTS FROM A MATHEMATICAL MODEL

    May 1, 2008, 00:00

  • PRS25 VALIDATION OF CLAIMS-BASED PERSISTENT ASTHMA SEVERITY CLASSIFICATION

    May 1, 2008, 00:00

  • PMH74 IMPACT OF ALTERNATIVE TREATMENTS ON POST TREATMENT COSTS FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PDB48 LOST PRODUCTIVITY ASSOCIATED WITH TYPE I AND TYPE 2 DIABETES IN A COMMERCIALLY-INSURED POPULATION

    May 1, 2008, 00:00

  • PHP50 A TYPOLOGY OF AFRICAN AMERICAN COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND ITS CORRELATES FROM THE ANDERSEN HEALTH CARE UTILIZATION MODEL

    May 1, 2008, 00:00

  • AC3 DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTSWITH INSOMNIA

    May 1, 2008, 00:00

  • PCN87 USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY PROMOTIONAL MATERIALS

    May 1, 2008, 00:00

  • PUK25 DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S.

    May 1, 2008, 00:00

  • PMC23 PREDICTION MODELS FOR TRANSITIONS IN THE ELDERLY USING ADMINISTRATIVE CLAIMS

    May 1, 2008, 00:00

  • PMC52 THE DEVELOPMENT OFTHE PROGNOSTIC PROPENSITY SCORE- UTILIZED TO PROVIDE PHYSICIANS WITH DETAILED EVIDENCE TO ALLOW FOR OPTIMAL PRESCRIBING

    May 1, 2008, 00:00

  • PSS25 PHARMACOECONOMIC STUDY OF WET AGE-RELATED MACULAR DEGENERATION (AND)TREATMENT IN MEXICO

    May 1, 2008, 00:00

  • PDB76 PROFILING PHYSICIAN PRESCRIPTION BEHAVIORWITH CANONICAL CORRESPONDENCE ANALYSIS

    May 1, 2008, 00:00

  • PMS1 EFFECT OF BISPHOSPHONATES ON FRACTURES IN POSTMEOPAUSALWOMEN-A SYSTEMATIC LITERATURE REVIEW

    May 1, 2008, 00:00

  • PHP65 THE ROLE OF THE ACADEMY OF MANAGED CARE PHARMACY (AMCP) FORMAT IN MANAGED CARE FORMULARY AND COVERAGE DECISIONMAKING

    May 1, 2008, 00:00

  • PGI1 HETEROGENEITY ACROSS RANDOMIZED CONTROLLED TRIALS OF PROTON-PUMP INHIBITORS IN NIGHTTIME GERD- A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PSS29 USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS- RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX

    May 1, 2008, 00:00

  • PSS47 AN OBSERVATIONAL DATABASE ANALYSIS OF TREATMENT PATTERNS OF PATIENTS WITH PSORIASIS

    May 1, 2008, 00:00

  • PHP81 PROGRESSIVE LICENSING AND VALUE FOR MONEY- USE OF RESPONDERANALYSIS IN ECONOMIC EVALUATION

    May 1, 2008, 00:00

  • PHP7 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON OUTCOMES AMONG ADULTS INTHE UNITED STATES

    May 1, 2008, 00:00

  • PHC6 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN HUNGARY

    May 1, 2008, 00:00

  • PCN31 A PROBABILISTIC DECISION MODEL TO GUIDE OPTIMAL HEALTH POLICY DECISIONS FOR LUNG CANCER SCREENING

    May 1, 2008, 00:00

  • PCN14 A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES OF HER2 TESTING TRASTUZUMAB THERAPY

    May 1, 2008, 00:00

  • PIN38 RANDOMIZED CONTROLLED TRIAL OF TELEPHONE, EMAIL AND TEXT MESSAGING REMINDERS ON PATIENT COMPLIANCE WITH ANTIBIOTIC REGIMEN

    May 1, 2008, 00:00

  • PMH6 OPTIMAL THRESHOLDS OF EARLY NON-RESPONSE TO ATYPICAL ANTIPSYCHOTICS- APPLICATION OF SIGNAL DETECTION ANALYSIS

    May 1, 2008, 00:00

  • PMC12 MEASURING ECONOMIC AND CLINICAL OUTCOMES ASSOCIATED WITHTELE-ICU MONITORING

    May 1, 2008, 00:00

  • PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)

    May 1, 2008, 00:00

  • PCV25 IMPROVEMENTS IN CARDIOVASCULAR DISEASE OUTCOMES IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES

    May 1, 2008, 00:00

  • PUK17 ECONOMIC EVALUATION OF SEVELAMER VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS ON DIALYSIS IN THE UNITED KINGDOM SETTING

    May 1, 2008, 00:00

  • CASE 1 AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL HTA PROCESSTO SET MEDICALAND PAYMENT POLICY IN A U.S. COMMERCIAL HEALTH PLAN

    May 1, 2008, 00:00

  • PGI14 COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE- SHOULD EMERGING SAFETY CONCERNS AFFECT THERAPEUTIC DECISION-MAKING?

    May 1, 2008, 00:00

  • PSY44 LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL FOR USE IN INTERNATIONAL STUDIES

    May 1, 2008, 00:00

  • PIN49 SPREAD PATTERN FORMATION OF H5NI-AVIAN INFLUENZA AND ITS IMPLICATIONS FOR CONTROL STRATEGIES

    May 1, 2008, 00:00

  • PIN25 THE ECONOMIC IMPACT OF SINGLE-DOSE AZITHROMYCIN MICROSPHERES FORMULATION FORTHE MANAGEMENT OF ACUTE STREPTOCOCCAL PHARYNGITIS (ASP) IN MEXICO

    May 1, 2008, 00:00

  • PSY38 FACTORS ASSOCIATED WITH LOWER HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN ADULTS WITH FACTORVIII DEFICIENCY-THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)

    May 1, 2008, 00:00

  • PMH60 HEALTH STATUS ANDWORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS AND DEPRESSION

    May 1, 2008, 00:00

  • PHP48 THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS EVALUATION RESEARCH IN ZIMBABWE

    May 1, 2008, 00:00

  • PGI3 COST OF PATIENT CARE IN PATIENTS WITH ULCERATIVE COLITIS IN BRAZIL- PUBLIC HEALTH PERSPECTIVE

    May 1, 2008, 00:00

  • PCN10 CANCER RISK BETWEEN ATORVASTATIN AND SIMVASTATIN IN THE LOUISIANA MEDICAID PATIENTS

    May 1, 2008, 00:00

  • PND8 MEDICAL COSTS ASSOCIATED WITHTREATMENT CHANGE IN MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PHC4 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER I YEARAFTER TOTAL HIP REPLACEMENT IN VETERAN PATIENTS

    May 1, 2008, 00:00

  • PCN65 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA RECEIVING 90Y-IBRITUMOMABTIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY

    May 1, 2008, 00:00

  • PCV38 BOSENTAN IS A COST-EFFECTIVE TREATMENT FOR UNITED KINGDOM PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION OF WHO CLASS III

    May 1, 2008, 00:00

  • PCV4 APPROPRIATE UTILIZATION AND COST-ANALYSIS OF ADD-ON EZETIMBE LIPID-LOWERING THERAPY AT THE VETERANS AFFAIRS SAN DIEGO HEALTH CARE SYSTEM (VASDHS)

    May 1, 2008, 00:00

  • PDB32 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OFACROMEGALY IN MEXICO

    May 1, 2008, 00:00

  • PHC12 STARR PROCEDURE FOR OBSTRUCTED DEFAECATION SYNDROME (ODS)- 12-MONTH FOLLOW-UP

    May 1, 2008, 00:00

  • PRS5 IMPACT OF TOBACCO SMOKE EXPOSURE ON EXACERBATION FREQUENCY, SEVERITY, AND INHALER USE IN ASTHMATIC CHILDREN

    May 1, 2008, 00:00

  • PND27 RELATIONSHIP BETWEEN GAPS IN DRUGTREATMENT FOR MULTIPLE SCLEROSIS AND INCIDENCE OF EXACERBATIONS- FINDINGS FROM A NATIONAL MANAGED CARE DATABASE

    May 1, 2008, 00:00

  • PCN92 THE WAR ON CANCER- AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL

    May 1, 2008, 00:00

  • PIH19 PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME (PMS) AND PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING PHYSICAL COMPONENT SUMMARY (PCS) SCORE

    May 1, 2008, 00:00

  • PDB33 COST MINIMIZATION ANALYSIS OF DIFFERENT GROWTH HORMONE DEVICES BASED ON TIME-AND-MOTION SIMULATIONS

    May 1, 2008, 00:00

  • DU2 DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE ACCESS TO DRUGS AND HEALTH CARE FORTHE POOREST IN AFRICA?

    May 1, 2008, 00:00

  • PCV68 CLINICAL DETERMINANTS OF SATISFACTION AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CARDIAC DISEASE AND DYSLIPIDEMIA

    May 1, 2008, 00:00

  • PMH52 COSTS OF NON-COMPLIANCE WITH ANTIPSYCHOTIC MEDICATIONS AMONG PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • AC8 ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY

    May 1, 2008, 00:00

  • PCV11 ASSESSMENT AND QUANTIFICATION OF THE BENEFIT RISK RATIO OF ROSUVASTATIN AND ATORVASTATIN FROM A META-ANALYSIS OF HEAD TO HEAD RANDOMISED CONTROLLED TRIALS

    May 1, 2008, 00:00

  • PIN45 COMPREHENSIVE EDUCATIONAL APPROACH HOWTO INFLUENCE PRESCRIPTION HABITS AND ANTIBIOTIC RESISTANCE IN AMBULATORY PRACTICE

    May 1, 2008, 00:00

  • PCV100 THE EFFECTIVENESS OF A PATIENT AND PHYSICIAN EDUCATIONAL PROGRAM IN INITIATING STATIN THERAPY AMONG DIABETICS

    May 1, 2008, 00:00

  • PRS10 ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB USE FORTREATING ASTHMA IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PCN57 COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER

    May 1, 2008, 00:00

  • WH3 CLINICAL AND ECONOMIC OUTCOMESAMONGWOMEN USING LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS)

    May 1, 2008, 00:00

  • PMH61 PATIENT PREFERENCES IN THE THERAPY OF ADHD-A DISCRETE CHOICE EXPERIMENT

    May 1, 2008, 00:00

  • PHP52 CHANGES IN PHARMACIST-PROVIDED MEDICATION THERAPY MANAGEMENT SERVICES- ANALYSIS OF ONE INNOVATIVE COMPANYS MTM SERVICE CLAIMS OVERTIME

    May 1, 2008, 00:00

  • PHP76 ALBERTAS HEALTH SYSTEM PERFORMANCES BALANCED SCORECARD STUDY

    May 1, 2008, 00:00

  • DH2 IMPACT OF ADHERING TO LIPID MANAGEMENT NATIONAL GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR EVENTS AND COSTS IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PCN84 CLINICAL AND ECONOMIC OUTCOMES FOR CANCER CHEMOTHERAPY PATIENTS WHEN INITIATED ON ERYTHROPOIESIS-STIMULATING AGENTS (ESA) AT BASELINE (BL) HEMOGLOBIN (HB) I0G/DL

    May 1, 2008, 00:00

  • PCN34 COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER- A MARKOV MODEL-BASED ANALYSIS

    May 1, 2008, 00:00

  • PRS36 FACTORS ASSOCIATED WITH ANTIHISTAMINE PRESCRIBING IN ASTHMA IN THE UNITED STATES IN 2005

    May 1, 2008, 00:00

  • PCV23 MEDICAL CLAIMS FOR GASTROINTESTINAL ADVERSE EVENTS ARE COMMON IN PATIENTS PRESCRIBED CLOPIDOGREL

    May 1, 2008, 00:00

  • PCV71 PSYCHOLOGICAL FACTORS AS PREDICTORS OF CARDIOVASCULAR RISK IN A PROSPECTIVE STUDY COHORT IN THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PIN16 COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA

    May 1, 2008, 00:00

  • MD3 IMPACT OF MEDICARE PART D DOUGHNUT HOLE ONTHE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES

    May 1, 2008, 00:00

  • DU1 DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION-ANALYSIS OF UNITED STATES NATIONAL DATA 2000-2005

    May 1, 2008, 00:00

  • PMH1 ESTIMATING THE MAGNITUDE OF ORAL ANTIPSYCHOTIC DRUG-DRUG INTERACTIONS

    May 1, 2008, 00:00

  • PMH68 CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWINGTHE INTRODUCTION OF DULOXETINE- A 24 MONTHS STUDY

    May 1, 2008, 00:00

  • PGI21 A COMPARISON OF TEST-RETEST RELIABILITY OF SELF-REPORTED SF-36, WHOQOL, AND EQ-5D QUESTIONNAIRES BASED ON DIFFERENT ADMINISTRATION APPROACHES

    May 1, 2008, 00:00

  • PSY45 EVALUATION OF THE NEUROPATHIC PAIN SYMPTOM INVENTORY- CONCEPTUAL ADEQUACY IN SIX COUNTRIES

    May 1, 2008, 00:00

  • PMC26 APPLICATION OFTHE FRAMEWORK FOR EVALUATING COMPLEX INTERVENTIONS TO CLUSTER RANDOMIZED TRIALS FOR THE EVALUATION OF DISEASE MANAGEMENT PROGRAMS

    May 1, 2008, 00:00

  • PHP17 HOW MANDATORY PRICE REDUCTION OF REIMBURSED PHARMACEUTICALS COULD RESULT IN INCREASED PHARMACEUTICAL EXPENDITURE?

    May 1, 2008, 00:00

  • PSY1 META-ANALYSIS OF ANTICONVULSANTS, SNRIS ANDTCAS IN TREATING NEUROPATHIC PAIN

    May 1, 2008, 00:00

  • PCN4 DATA ANALYSIS WITH GENERALIZED LINEAR MODELS ON LUNG CANCER DATA

    May 1, 2008, 00:00

  • PIH23 PATIENT SATISFACTION WITH ERECTILE DYSFUNCTION TREATMENT- SILDENAFIL VS. FOOD SUPPLEMENTS

    May 1, 2008, 00:00

  • PCV7 RISK OF HOSPITALIZATION ASSOCIATED WITH BETA-BLOCKERTHERAPY IN PATIENTS OF CHRONIC HEART FAILURE AND DIABETES- A MEDIC AID STUDY

    May 1, 2008, 00:00

  • PCV97 IS THERE A LEARNING CURVE ASSOCIATED WITH EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE?

    May 1, 2008, 00:00

  • PIN22 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS- A DECISION TREE MODEL FOR CANADA

    May 1, 2008, 00:00

  • PMS28 REAL WORLD COSTS AND DOSING PATTERNS OF ABATACEPT AND INFLIXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2008, 00:00

  • PCV103 THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY

    May 1, 2008, 00:00

  • PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER

    May 1, 2008, 00:00

  • PCV49 ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION AND AFTER MAJOR ORTHOPAEDIC SURGERY-RESULTS OF A SYSTEMATIC LITERATURE REVIEW

    May 1, 2008, 00:00

  • PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2008, 00:00

  • DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL- A PATIENT-LEVEL APPROACH USING QUEBECS PROVINCIAL HEALTH PLAN DATA

    May 1, 2008, 00:00

  • PRS15 THE BURDEN OF NASAL CONGESTION IN THE UNITED STATES

    May 1, 2008, 00:00

  • PMS26 TRENDS IN HOSPITALIZATIONS AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2002-2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA

    May 1, 2008, 00:00

  • PIN30 COST-MINIMIZATION ANALYSIS OF ORALVALGANCICLOVIR VERSUS INTRAVENOUS GANCICLOVIR FORTHE PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS IN BRAZIL

    May 1, 2008, 00:00

  • PR4 EVALUATION OF IMPACT OF ORALTOPOTECAN ON HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL CELL LUNG CANCER

    May 1, 2008, 00:00

  • PSS27 USING MEDICATION POSSESSION AND DAYS OF COVERAGE ON THERAPYTO ASSESS PERSISTENCE WITH PROSTAGLANDIN OCULAR HYPOTENSIVE THERAPY

    May 1, 2008, 00:00

  • AC6 ASSOCIATION OF NONCOMPLIANCE WITH DIABETES CARE GUIDELINES AND DISEASE BURDEN IN A CALIFORNIA MEDICAID TYPE 2 DIABETES MELLITUS POPULATION

    May 1, 2008, 00:00

  • PHP58 ECONOMIC-BASED OUTCOMES ASSESSMENT OF PHARMACEUTICAL CARE IN A UNIVERSITY HOSPITAL MEDICAL INTENSIVE CARE UNIT IN TAIWAN

    May 1, 2008, 00:00

  • PND31 CO-MORBID INSOMNIA IN PRIMARY CARE PATIENTS AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQL) INDEPENDENT OF OTHER FACTORS

    May 1, 2008, 00:00

  • PCN75 BURDEN OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PDB29 PHARMACOECONOMIC EVALUATION OF CABERGOLINE FOR THE MANAGEMENT OF HYPERPROLACTINEMIA CAUSED BY HYPOPHYSEAL MICROADENOMA IN MEXICO

    May 1, 2008, 00:00

  • PMC33 PREDICTING A MEAN EQ-5D PREFERENCE-BASED SCORE FROMTHE 8 MEAN SF-36 DIMENSION SCORESWHEN INDIVIDUAL DATA IS NOT AVAILABLE

    May 1, 2008, 00:00

  • PUK23 EVALUATION OF FACE AND CONTENT VALIDITY OF NOCTURIA QUALITY OF LIFE QUESTIONNAIRE (N-QOL)

    May 1, 2008, 00:00

  • PIN46 COUNTRY ASSESSMENT TO DETERMINE FACTORS INFLUENCING THE COST, AVAILABILITY AND DISTRIBUTION OF ACYCLOVIR IN EIGHT SUB-SAHARAN AFRICAN COUNTRIES

    May 1, 2008, 00:00

  • The Impact of Body Weight on Patient Utilities with or without Type 2 Diabetes- A Review of the Medical Literature

    May 1, 2008, 00:00

  • PGI13 DIRECT ECONOMIC BURDEN OF CHRONIC HEPATITIS C VIRUS IN A LARGE MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PDB72 THE NEED FOR EARLIER INSULIN INITIATION AND INTENSIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES- EVIDENCE FROM HEALTH CLAIMS AND LABORATORY DATABASE

    May 1, 2008, 00:00

  • PCV55 THIRY-DAY RESOURCE USE DIARY DATA FROM THE BURST STUDY

    May 1, 2008, 00:00

  • AC4 THE COST OF NON-ADHERENCETO ASTHMATREATMENT GUIDELINES AMONG A LOW-INCOME COHORT

    May 1, 2008, 00:00

  • PCN35 COST-EFFECTIVENESS ANALYSIS OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT OR INTOLERANT CML PATIENTS IN BRAZIL

    May 1, 2008, 00:00

  • PCV1 A MODIFIED RXRISK-V COMORBIDITY INDEX PREDICTS ADHERENCE WITH LIPID LOWERINGTHERAPY (LLT)

    May 1, 2008, 00:00

  • PCN29 SCREENING, PREVENTION, AND TREATMENT OF CERVICAL CANCER-A GLOBAL AND REGIONAL GENERALIZED COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PSY37 RESOURCE USE AND COSTS ASSOCIATED WITH BACK PAIN IN GERMANY

    May 1, 2008, 00:00

  • PRS46 HOW PROCESS INFLUENCES SCIENTIFIC EVIDENCE FOR HEALTH CARE POLICYMAKERS. THE CASE OF ECONOMICS AND MEDICAL DECISION-MAKING PROCESSES

    May 1, 2008, 00:00

  • PRS33 TREATMENT SATISFACTION QUESTIONNAIRES IN ASTHMA AND OTHER CHRONIC DISEASES

    May 1, 2008, 00:00

  • PRS43 ECONOMIC BURDEN OF ASTHMA AMONG CHILDREN IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSS18 COST-EFFECTIVENESS OF THE BIOLOGIC AGENTS UTILIZED IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS- A MARKOV MODEL

    May 1, 2008, 00:00

  • PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

    May 1, 2008, 00:00

  • PCN49 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARYTO BREAST, LUNG, OR PROSTATE CANCER

    May 1, 2008, 00:00

  • PCN40 CONTROLLING FOR POTENTIAL CENSORING BIAS ON DEPENDENT VARIABLES

    May 1, 2008, 00:00

  • PIN31 TOTAL TREATMENT COST OF LINEZOLID COMPARED TO VANCOMYCIN IN MRSA INFECTIONS

    May 1, 2008, 00:00

  • PHP55 DEVELOPING A PRACTICE -BASED RESEARCH NETWORK (PBRN)TO EVALUATE MULTI-CENTER PHARMACIST-CONDUCTED MEDICATION THERAPY MANAGEMENT PROGRAMS (MTMPS) USING THE ECHO MODEL

    May 1, 2008, 00:00

  • PSS39 ESTIMATING HEALTH RELATED UTILITY FROM SYMPTOM SEVERITY IN ATOPIC DERMATITIS (ECZEMA)

    May 1, 2008, 00:00

  • PCV80 NATIONAL ESTIMATES OF ENROLLMENT IN DISEASE STATE MANAGEMENT PROGRAMS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PDB44 COST-EFFECTIVENESS OF THE USE OF ANGIOTENSIN-II-RECEPTER BLOCKERS IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY IN JAPAN

    May 1, 2008, 00:00

  • PHC5 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER ONEYEAR AFTERTOTAL KNEE REPLACEMENT IN VETERAN PATIENTS

    May 1, 2008, 00:00

  • PMH80 THE CHANGE OF PRICES AND EXPENDITURES OFTHE ORIGINAL AND GENERIC DRUGS OF FLUOXETINE-A LONGITUDINAL ANALYSIS ON REIMBURSEMENT DATABASE OFTHE NATIONAL HEALTH INSURANCE

    May 1, 2008, 00:00

  • PSY31 GREATER SEVERITY OF ILLNESS, RISK OF MORTALITY, LENGTH-OF-STAY, AND HOSPITAL COSTS IN PATIENTS WITH HYPONATREMIA

    May 1, 2008, 00:00

  • PSS42 MAPPING THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (NEI-VFQ 25) TO THE INDEX VALUES FOR THE EQ-5D-A COMPARISON OF MODELS

    May 1, 2008, 00:00

  • PIN19 ECONOMICAL EVALUATION OF DARUNAVIR LOW DOSE RITONAVIR IN TREATMENT-EXPERIENCED HIV-I-INFECTED PATIENTS

    May 1, 2008, 00:00

  • PDB4 ESTIMATION OF STUDY POPULATION SIZE FOR EFFECTIVENESS OUTCOMES AT 6 AND 12 MONTHS VIA ELECTRONIC MEDICAL RECORDS

    May 1, 2008, 00:00

  • PMH16 METABOLIC SAFETY AND TOLERABILITY OF ZIPRASIDONE VS. OLANZAPINE IN SCHIZOPHRENIA PATIENTS- SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2008, 00:00

  • PMC45 EQ-5D VAS = PRO

    May 1, 2008, 00:00

  • PDB41 MEDICAL CARE OF PATIENTS WITH DIABETIC NEUROPATHY- IMPACT OF TYPE I DIABETES AND PRESENCE OF OTHER DIABETES-RELATED COMPLICATIONS

    May 1, 2008, 00:00

  • PRS42 ASTHMA DISEASE BURDEN, EVIDENTIARY REQUIREMENTS, AND FORMULARY CONSIDERATIONS AMONG MANAGED CARE AND EMPLOYER DECISION MAKERS REGARDING INHALED CORTICOSTEROIDS (ICS)

    May 1, 2008, 00:00

  • PMH21 PHARMACY COST IMPACT OF GUIDELINE-RECOMMENDED DOSING OF SECOND GERNERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PMH53 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PHP66 EVALUATION OF INDIRECT COMPARISONS USED FOR REIMBURSEMENT DECISIONS- LESSONS FROM THE COMMON DRUG REVIEW

    May 1, 2008, 00:00

  • PSY40 SYSTEMATIC REVIEW OFTHE PSYCHOMETRIC PROPERTIES OFTHE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-ANEMIA (FACT-AN) FOR ANEMIC CANCER PATIENTS

    May 1, 2008, 00:00

  • PCV63 BARRIERS AND MOTIVATORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AND BLOOD PRESSURE CONTROL AMONG AFRICAN AMERICANS FROM ALABAMA

    May 1, 2008, 00:00

  • PCV57 PREVALENCE OF UNDERUTILIZATION OF INITIATED STATIN THERAPY AND RENIN-ANGIOTENSIN SYSTEM BLOCKADE

    May 1, 2008, 00:00

  • PCN44 INCIDENCE AND COSTS OF TREATMENT-RELATED COMPLICATIONS AMONG PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

    May 1, 2008, 00:00

  • PCN61 EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER

    May 1, 2008, 00:00

  • PCN21 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN) IN TREATMENT OF HER2-POSITIVE BREAST CANCER

    May 1, 2008, 00:00

  • PCN5 META-ANALYSIS ON THE MORBIDITY AND MORTALITY OF CLODRONATE, PAMIDRONATE AND ZOLEDRONATE IN PATIENTS WITH BONE METASTASES

    May 1, 2008, 00:00

  • PCV87 PHYSICIAN AND PATIENT FACTORS PREDICTING THE PRESCRIBING OF STATINS IN HYPERTENSION AND DIABETES

    May 1, 2008, 00:00

  • PHP8 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON INDIRECT COSTS AMONG ADULTS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PMC46 DEVELOPMENT OF A STANDARDIZED CLASSIFICATION SYSTEM FOR THE TRANSLATIONS OF PRO INSTRUMENTS

    May 1, 2008, 00:00

  • PGI23 PATIENT REPORTED PREVALENCE AND SEVERITY OF CONSTIPATION IN HOSPICE PATIENTS

    May 1, 2008, 00:00

  • PMH57 MEDICATION PERSISTENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DEMENTIA- A LONGITUDINAL COHORT STUDY

    May 1, 2008, 00:00

  • PHP10 CREATION OF A RISK RATING SYSTEMTO COMMUNICATE DRUG SAFETY INFORMATIONTO CONSUMERS

    May 1, 2008, 00:00

  • PSS26 USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)

    May 1, 2008, 00:00

  • PUK9 HEALTH ECONOMIC EVALUATION OF PARICALCITOL COMPARED TO NON-SELECTIVE VITAMIN D RECEPTOR ACTIVATOR FORTHETREATMENT OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE PATIENTS- US PERSPECTIVE

    May 1, 2008, 00:00

  • PMC38 USE OF A MOBILE PHONETO ADMINISTER VISUAL ANALOGUE SCALES (VAS)

    May 1, 2008, 00:00

  • PDB34 ASSESSING DIFFERENCES IN UTILIZATION AND COSTS BETWEEN INSULIN DETEMIR (LEVEMIR) AND INSULIN GLARGINE (LANTUS) USERS

    May 1, 2008, 00:00

  • PHP72 GENETIC TESTING FOR WARFARIN INITIATION- A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE

    May 1, 2008, 00:00

  • PSY43 DISCOVERING THE STRUCTURE OFTHE POWER OF FOOD SCALE (PFS) IN OBESE PATIENTS

    May 1, 2008, 00:00

  • IN4 COST-EFFECTIVENESS OF DORIPENEM INTHETREATMENT OF NOSOCOMIAL PNEUMONIA

    May 1, 2008, 00:00

  • PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE I DIABETES MELLITUS (TIDM) IN THE CANADIAN PAYER SETTING- MODELING ANALYSIS USING A RANDOMIZED CONTROLLED TRIAL

    May 1, 2008, 00:00

  • PIN4 ANTIMICROBIAL RESISTANCE PREVALENCE OF ENTEROCOCCI FROM BOGOTA, COLOMBIA HOSPITALS 2001-2006

    May 1, 2008, 00:00

  • PMC35 A SYSTEMATIC REVIEW OF APPLICATIONS OF CONJOINT ANALYSIS IN MEDICINE

    May 1, 2008, 00:00

  • PMS8 HEALTH ECONOMICS MODEL FORTOTAL HIP ARTHROPLASTY- COST SAVINGS ACHIEVED BY NEWER TECHNOLOGY

    May 1, 2008, 00:00

  • PMH76 COST ESTIMATION OF PSYCHIATRIC CARE IN THE JAPANESE HOSPITAL USING SYSTEM DYNAMICS SIMULATION

    May 1, 2008, 00:00

  • PCV46 COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005

    May 1, 2008, 00:00

  • PCN59 TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE CANCER SURVIVORS IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • PIH2 CONTRACEPTIVE FAILURE RATES AMONG MEDICAID AND NON-MEDICAID ENROLLEES

    May 1, 2008, 00:00

  • Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip

    May 1, 2008, 00:00

  • PMH39 THE PREVALENCE AND COSTS OF METABOLIC CONDITIONS AMONG PATIENTS WITH BIPOLAR DISORDERS AS COMPARED TO MATCHED CONTROLS

    May 1, 2008, 00:00

  • CA2 THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BYTHE ONTARIO CANCER DRUG APPROVAL COMMITTEE

    May 1, 2008, 00:00

  • PIN7 MRSA- INVESTIGATING THE DANGEROUS HOSPITAL INFECTION

    May 1, 2008, 00:00

  • PRS11 LONG TERM COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS FOR SMOKING CESSATION IN CZECH REPUBLIC

    May 1, 2008, 00:00

  • PMH82 PREVALENCE AND PATTERNS OF NEWER ANTIDEPRSSANTS USED IN CHILDREN AND ADOLESCENTS IN A STATE MEDICAID PROGRAM OVER SEVENYEARS

    May 1, 2008, 00:00

  • PCV40 COST-EFFECTIVENESS ANALYSIS OF DRUG-ELUTING STENT VS BARE METAL STENT IN PATIENTS WITH ISCHAEMIC HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE.

    May 1, 2008, 00:00

  • PDB62 DETERMINANTS OF INSULIN INITIATION FOR PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PIH17 COST-EFFECTIVENESS OF MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND SURGERY FOR TREATMENT OF UTERINE FIBROIDS

    May 1, 2008, 00:00

  • PRS21 MEDICATION ADHERENCE AND PERSISTENCE IN THE LAST YEAR OF LIFE IN COPD PATIENTS

    May 1, 2008, 00:00

  • PIN40 ASSESSMENT OF THE CROSS-CULTURAL VALIDITY OF AN HIV SYMPTOM DISTRESS MODULE IN AN INTERNATIONAL HIV CLINICAL TRIAL

    May 1, 2008, 00:00

  • PMC10 THE DEVELOPMENT OF COST-EFFECTIVENESS INDICES WITH EQUITY IMPLICATIONS FOR THE ECONOMIC EVALUATION OF HEALTH CARE

    May 1, 2008, 00:00

  • Diabetes-Specific or Generic Measures for Health-Related Quality of Life? Evidence from Psychometric Validation of the D-39 and SF-36

    May 1, 2008, 00:00

  • PSS5 MEDICAL COST OF GLAUCOMA IN SWEDEN

    May 1, 2008, 00:00

  • PCV43 OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF CORONARY ARTERY DISEASE IN CHINA WITH USE OF CORONARY CT ANGIOGRAPHY

    May 1, 2008, 00:00

  • PND45 USE OF DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS- A POPULATION BASED STUDY

    May 1, 2008, 00:00

  • PHP27 ESTIMATION AND COMPARISON OF ORTHOTIC BRACE COSTS WITH REIMBURSEMENT TARIFFS AND RETAIL PRICES IN BELGIUM

    May 1, 2008, 00:00

  • PMS40 ORALVS INJECTABLE TREATMENTS- PATIENT PREFERENCE IN BRAZILIAN PATIENTS

    May 1, 2008, 00:00

  • PMH87 SUPPORTING PRODUCT CLAIMS IN DRUG DEVELOPMENT- A FRAMEWORK FOR INTEGRATING PATIENT REPORTED OUTCOMES AND HEALTH ECONOMICS CONCEPTS AND ENDPOINTS

    May 1, 2008, 00:00

  • PCN1 DIAGNOSIS OF HER2 PROTEIN OVEREXPRESSION IN PATIENTS WITH BREAST CANCER IN BRAZIL

    May 1, 2008, 00:00

  • PDB2 HBAIC GOAL ATTAINMENT IN RELATION TO DOSE AMONG DIABETES PATIENTS USING METFORMIN

    May 1, 2008, 00:00

  • PDB12 CLINICAL AND ECONOMIC OUTCOMES RELATED TO A PAY-FOR-PERFORMANCE PROGRAM

    May 1, 2008, 00:00

  • PIN2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FORTHETREATMENT OF HEPATITIS B

    May 1, 2008, 00:00

  • PND23 MIGRAINE SUFFERERS SHOW SIGNIFICANT HEALTH CARE UTILIZATION AND EXPENDITURES

    May 1, 2008, 00:00

  • PCV86 PATTERNS OF DIURETIC USE IN MULTI-DRUG ANTI-HYPERTENSIVE REGIMENS IN THE POSTALLHAT ERA

    May 1, 2008, 00:00

  • PSS50 TRENDS IN MEDICATION PRESCRIBING FOR ACNE IN THE UNITED STATES ACCORDING TO PATIENT AGE

    May 1, 2008, 00:00

  • PHP39 THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS TREATED WITH HEPARIN DURING HOSPITALIZATION

    May 1, 2008, 00:00

  • PSY19 PHARMACOECONOMIC EVALUATION OF TREATMENT OF HAIRY CELL LEUKEMIA

    May 1, 2008, 00:00

  • PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT

    May 1, 2008, 00:00

  • PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY- INFLUENCE ON HOSPITALIZATION

    May 1, 2008, 00:00

  • PHP14 ESTIMATION OF USAGE OF NEW DRUG AFTER REIMBURSEMENT FOR BUDGET IMPACT ANALYSIS

    May 1, 2008, 00:00

  • PHP5 ADHERENCE AND SWITCHING WITH DRUGS USED FOR THE PROPHYLAXIS OF ORGAN REJECTION

    May 1, 2008, 00:00

  • PIN32 THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY-LINKING SURVEY AND CLAIMS DATA TO UNDERSTAND DISEASE IMPACT ON INDIRECT COSTS

    May 1, 2008, 00:00

  • PSS9 A COST-EFFECTIVENESS ANALYSIS OFTNF-ALPHA INHIBITORS IN COMPARISON TO OTHER STRATEGIES IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS- A DECISION ANALYSIS MODEL

    May 1, 2008, 00:00

  • PSY20 COST-EFFECTIVENESS ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENTS FOR BONE MARROWTRANSPLANTATION IN PATIENTS WITH APLASTIC ANEMIA IN MEXICO

    May 1, 2008, 00:00

  • PND16 THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND PRESCRIPTION DRUG EXPENDITURES IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2008, 00:00

  • PMS35 QUALITY OF LIFE AMONG OUTPATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-LIFE SETTING IN GERMANY

    May 1, 2008, 00:00

  • PHP36 RELATIONSHIP OF DOCTOR SHOPPING AND POLYPHARMACY-A NATIONWIDE STUDY IN TAIWAN

    May 1, 2008, 00:00

  • PMS36 IMPROVEMENT IN SLEEP QUALITY FROM ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2008, 00:00

  • PUK7 COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY

    May 1, 2008, 00:00

  • PMH71 PREVALENCE OF CONCOMITANT USE OF ANTICHOLINERGIC MEDICATIONS AND CHOLINESTERASE INHIBITORS IN A MEDICAID NURSING HOME POPULATION

    May 1, 2008, 00:00

  • PDB39 FACTORS ASSOCIATED WITH HIGH TREATMENT CHARGES IN PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PSY5 CROSS-CULTURAL COMPARISONS OFTHE OVERWEIGHT/OBESE POPULATION IN THE US AND EUROPE

    May 1, 2008, 00:00

  • Reliability of Two Instruments for Critical Assessment of Economic Evaluations

    May 1, 2008, 00:00

  • PIH5 THE EFFECT OF INJURY SEVERITY ON THE INCIDENCE AND RESOURCE UTILIZATION-RELATED OUTCOMES OF DEEP VEIN THROMBOSIS AMONG PEDIATRIC TRAUMA ADMISSIONS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PMC24 INVERSE PROBABILITY WEIGHTED RANDOM EFFECT MODELS FOR ESTIMATION OF CENSORED OUTCOMES VARIABLES

    May 1, 2008, 00:00

  • OM3 WAS IT NICE FORYOU? ESTIMATING SUBGROUP QUALITY OF LIFE TARIFFS FROM CONJOINT ANALYSES- RESULTS FROM A BEST-WORST SCALING STUDY

    May 1, 2008, 00:00

  • PSS43 WORK RELATED LOST PRODUCTIVITY AND ITS ECONOMIC IMPACT IN CANADIAN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    May 1, 2008, 00:00

  • PCN19 A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A TERTIARY CANCER CENTER

    May 1, 2008, 00:00

  • PIH13 A CONCEPTUAL FRAMEWORK TOWARD A MODIFIED REFERENCE CASE FOR DEVELOPING COUNTRIES- INCORPORATING DONOR FUNDING FLOWS IN COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PRS32 IMPACT OF UNCONTROLLED ASTHMA ON PRODUCTIVITY AND ACTIVITY IMPAIRMENT

    May 1, 2008, 00:00

  • PIH20 PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER USING MENTAL COMPONENT SUMMARY (MCS) SCORE

    May 1, 2008, 00:00

  • PIN39 ROLE OF DRUG DISTRIBUTION STRATEGIES TO IMPROVE HEALTH OUTCOME IN HIGH RISK PATIENTS

    May 1, 2008, 00:00

  • PND28 IMPROVEMENTS IN QUALITY OF LIFE FOLLOWING TREATMENT WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PIN41 COMPLEMENTARY AND ALTERNATIVE MEDICATION USE AND ADVERSE EVENTS IN HIV-INFECTED PATIENTS

    May 1, 2008, 00:00

  • PRS45 THE DEVELOPMENT AND VALIDATION OF A CONTEMPORARY ASTHMA POLICY MODEL

    May 1, 2008, 00:00

  • PMH26 IMPROVED WORK PRODUCTIVITY IN THE UNITED STATES (US) FOR PATIENTS TREATED WITH ESCITALOPRAM COMPARED TO DULOXETINE

    May 1, 2008, 00:00

  • PND32 DETERMINATION OFTHE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OFTHE 8-ITEM PARKINSONS DISEASE QUESTIONNAIRE (PDQ-8)

    May 1, 2008, 00:00

  • PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN

    May 1, 2008, 00:00

  • PIN23 PHARMACOECONOMIC ANALYSIS OF ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF NON NEUTROPENIC PATIENTS WITH INVASIVE CANDIDIASIS ATTHE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2008, 00:00

  • PMS2 COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

    May 1, 2008, 00:00

  • PCN6 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER I0YEARS IN 5 EUROPEAN COUNTRIES

    May 1, 2008, 00:00

  • PDB70 IMPACT OF ANEMIA ON HOSPITALIZATION COSTS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • PIH18 ASSESSING THE ASSOCIATION BETWEEN SCORE DIFFERENCES ON THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS) AND HEALTH-RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PMC3 METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF PER MEMBER PER MONTH (PMPM) UTILIZATION RATES

    May 1, 2008, 00:00

  • PCV70 PATIENT ADHERENCE TO CHOLESTEROL TREATMENT (PACT)- CANADIAN PHYSICIAN AND PATIENT PERSPECTIVES

    May 1, 2008, 00:00

  • PSS11 A COST-EFFECTIVENESS ANALYSIS OF BRIMONIDINE/TIMOLOL

    May 1, 2008, 00:00

  • PRS4 PROGNOSTIC FACTORS OF PATIENTS TRANSFERRED TO CHRONIC RESPIRATORY CARE WARD

    May 1, 2008, 00:00

  • PCV21 PREVALENCE, AWARENESS AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNITED STATES ADULTS AGED 65 AND OLDER

    May 1, 2008, 00:00

  • PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY

    May 1, 2008, 00:00

  • PHC1 A COST COMPARISON OF CARDIAC SURGERIES BY CHOICE OF FIBRIN SEALANT

    May 1, 2008, 00:00

  • PCV56 VOLUME AND MIX OF CARDIAC X-RAY PROCEDURES ACROSS U.S. HOSPITALS- UTILIZATION DATA TO SUPPORT FINANCIAL DECISIONS

    May 1, 2008, 00:00

  • PGI15 ECONOMIC EVALUATION OF PROTON PUMP INHIBITORS, RELATIVE TO ALTERNATIVE GASTROINTESTINAL PROPHYLAXIS AGENTS, FOR PREVENTION OF Gl COMPLICATIONS IN ELDERLY PATIENTS TAKING NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSNSAIDS)

    May 1, 2008, 00:00

  • PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS

    May 1, 2008, 00:00

  • PRS18 COST-UTILITY ANALYSIS OF VARENICLINE, AN ORAL SMOKING CESSATION DRUG, IN JAPAN

    May 1, 2008, 00:00

  • PMC1 SEARCH STRATEGIES AND RESULTS OF SYSTEMATIC REVIEWS

    May 1, 2008, 00:00

  • PCN2 SYSTEMATIC REVIEW OF PALONOSETRON IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

    May 1, 2008, 00:00

  • PHP73 CONSUMPTION PATTERNS AND ECONOMIC BURDEN OF DRUGS IN FORTALEZA, BRAZIL

    May 1, 2008, 00:00

  • PCN24 ECONOMIC EVALUATION OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA- AN UPDATED COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PIN21 COST-EFFECTIVENESS OF ANIDULAFUNGIN THERAPY IN CONFIRMED CANDIDEMIA AND OTHER FORMS OF INVASIVE CANDIDIASIS IN CANADA

    May 1, 2008, 00:00

  • PIH6 ECONOMIC ASSESSMENT OF SILDAFENIL FOR THE MANAGEMENT OF PATIENTS WITH ERECTILE DYSFUNCTION (ED) SECONDARYTO DIABETES MELLITUSTYPE 2 (DM2) AND HYPERTENSION IN MEXICO

    May 1, 2008, 00:00

  • PCN90 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS

    May 1, 2008, 00:00

  • PDB60 DISCREPANCIES BETWEEN IMPORTANCE AND EVALUATION OF INSULIN DELIVERY SYSTEM (IDS) FEATURES CONTRIBUTE TO IDS SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PRS31 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON CHILD AND CAREGIVER PRODUCTIVITY

    May 1, 2008, 00:00

  • PDB11 PREVALENCE OF AND RISK FACTORS FOR HOSPITALIZATIONS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA

    May 1, 2008, 00:00

  • PCN86 DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

    May 1, 2008, 00:00

  • DB3 REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE

    May 1, 2008, 00:00

  • PCV83 GENDER DISPARITIES IN THE UTILIZATION OF MYOCARDIAL PERFUSION IMAGING

    May 1, 2008, 00:00

  • PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE- A BAYESIAN META-ANALYSIS

    May 1, 2008, 00:00

  • PSY12 PROJECTED COST OF CARDIOMETABOLIC RISK FACTORS IN COMMERCIALLY INSURED NORMAL AND OVERWEIGHT PRIMARY CARE PATIENTS

    May 1, 2008, 00:00

  • PHP4 THE IMPACT OF COPAYMENTS OR BRAND NAMED DRUG ON MEDICATION PERSISTENCE

    May 1, 2008, 00:00

  • PMS16 ECONOMIC EVALUATION OF MONTHLY IBANDRONATE VS WEEKLY ALENDRONATE TO PREVENT OSTEOPOROTIC HIP FRACTURES IN MEXICAN WOMEN AGED FIFTY AND OLDER

    May 1, 2008, 00:00

  • PCV58 MODELING CARDIOVASCULAR HEALTH OUTCOMES IN MEDICAID HYPERTENSIVE PATIENTS-EFFECT OF PATIENT ADHERENCE

    May 1, 2008, 00:00

  • PHC7 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN POLAND

    May 1, 2008, 00:00

  • PSS36 COMPARISON OF THE QUALITY OF LIFE IMPACT OF PERIPHERAL VISION LOSS VERSUS CENTRAL VISION LOSS

    May 1, 2008, 00:00

  • PMC19 ESTIMATING SOCIODEMOGRAPHIC VARIABLES IN A PHARMACY DATASET- APPLYING DATA FROM US CENSUS 2000

    May 1, 2008, 00:00

  • HP2 NHS REIMBURSEMENT OF NEW CANCER DRUGS- IS NICE GETTING NASTIER?

    May 1, 2008, 00:00

  • PDB54 DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR A DIABETES-SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH

    May 1, 2008, 00:00

  • PRS8 HEALTH ECONOMICS OF ASTHMAASSESSING THE VALUE OF ASTHMA INTERVENTIONS

    May 1, 2008, 00:00

  • PMH78 EFFECTS OF DIRECT-TO-CONSUMER ADVERTISING AND DETAILING SPENDING ON ANTIDEPRESSANT SWITCH AND TREATMENT COMPLETION

    May 1, 2008, 00:00

  • PDB19 ECONOMIC EVALUATION OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF SHORT CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA)

    May 1, 2008, 00:00

  • PCV22 SIGMOID MAXIMUM EFFECT MODELING OF CORONARY HEART DISEASE DEATH AND MYOCARDIAL INFARCTION RATE VERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN STATIN SECONDARY PREVENTION TRIALS

    May 1, 2008, 00:00

  • PCN46 COMPARISON OF SURGICAL TREATMENT COSTS OF NONMELANOMA SKIN CANCER PATIENTS IN A UNIVERSITY-AFFILIATED PRACTICE

    May 1, 2008, 00:00

  • PSS2 EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS

    May 1, 2008, 00:00

  • PCV105 IMPACT OF GUIDELINES FORTREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN COMMUNITY HOSPITALS

    May 1, 2008, 00:00

  • DISCLOSURE INFORMATION

    May 1, 2008, 00:00

  • PGI12 HEALTH CARE COSTS RELATED TO THE TREATMENT OF CROHNS DISEASE

    May 1, 2008, 00:00

  • PSY6 THE PREVALENCE OF PAIN SYMPTOMS AMONG UNITED STATES ADULTS AGED 65 AND OLDER

    May 1, 2008, 00:00

  • PND6 MODELING THE IMPACT OF A FIXED-DOSE COMBINATION OF SUMATRIPTAN AND NAPROXEN SODIUM ONTRIPTAN CONSUMPTION IN A US MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • CV3 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLEEDING DURING CORONARY ARTERY BYPASS GRAFT SURGERY AMONG ELDERLY AMERICANS

    May 1, 2008, 00:00

  • PHP82 RECENT TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA

    May 1, 2008, 00:00

  • PIN17 DECISION ANALYTIC MODEL EVALUATING THE COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTION

    May 1, 2008, 00:00

  • PND29 REVIEW OF QUALITY OF LIFE INSTRUMENTS IN MIGRAINE

    May 1, 2008, 00:00

  • PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY- A MODEL APPROACH

    May 1, 2008, 00:00

  • PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL- AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)

    May 1, 2008, 00:00

  • PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES

    May 1, 2008, 00:00

  • PCV36 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES ON DIABETES MEDICATION

    May 1, 2008, 00:00

  • OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE

    May 1, 2008, 00:00

  • PCN85 EFFECT OF AGE AND PLACE OF RESIDENCE ON COLORECTAL CANCER TREATMENTS IN NEBRASKA CANCER REGISTRY FROM 1998 TO 2003

    May 1, 2008, 00:00

  • PIN50 INITIAL THERAPIES FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2008, 00:00

  • PMC48 SETTING THE OPTIMAL SCREENING TOOLTHRESHOLD FOR A CHRONIC UNDERDIAGNOSED ILLNESS- WHOSE BURDEN MATTERS MOST?

    May 1, 2008, 00:00

  • PMH30 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM OR DIVALPROEX- IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

    May 1, 2008, 00:00

  • PHP63 SEGMENTED REGRESSION ANALYSIS OF INTERRUPTED TIME SERIES PRESCRIPTION GROSS MARGIN TRENDS FOR INDEPENDENT PHARMACIES BEFORE AND AFTER MEDICARE PART D

    May 1, 2008, 00:00

  • PDB51 A RESTROSPECTIVE ANALYSIS OF MEDICATIONS ADHERENCE AND ASSOCIATED HEALTH CARE COST FOR THE DIABETIC PATIENTS

    May 1, 2008, 00:00

  • PSY47 IMPACT OF NIGHTTIME PAIN ON SLEEP QUALITY IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS

    May 1, 2008, 00:00

  • CA4 THE EARLY CLINICAL AND ECONOMIC BENEFITS OF ATORVASTATIN IN A CANADIAN SETTING

    May 1, 2008, 00:00

  • PMC42 METHODOLOGICAL ISSUES WITHTHE ANALYSIS OF PREFERENCE-BASED EQ-5D INDEX SCORE

    May 1, 2008, 00:00

  • PRS38 HEALTH CARE UTILIZATION CORRELATED WITH CONTROLLER DURATION DURING THE FIRST YEAR AFTER DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2008, 00:00

  • PDB28 COST-EFFECTIVENESS ANALYSIS OF DOPAMINE AGONISTS FOR THE TREATMENT OF INFERTILITY ASOCIATED TO HYPERPROLACTINEMIA IN MEXICO

    May 1, 2008, 00:00

  • PMS39 LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PRELIMINARY ANALYSIS USING MARKOV MODEL

    May 1, 2008, 00:00

  • PMS21 THE RELATIONSHIP BETWEEN COST OF ILLNESS AND DISEASE SEVERITY IN RHEUMATOID ARTHRITIS- RESULTS OF A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PSY13 THE HEALTH CARE COST EFFECTS OF DIABETES AMONG OBESE AND MORBIDLY OBESE ADULTS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCASE5 INFORMING DECISION MAKERS IN GERMANY- THE IQWIG APPROACH

    May 1, 2008, 00:00

  • PUK18 STAFF TIME AND COSTS FOR ANEMIA MANAGEMENT WITH ERYTHROPOIETIC STIMULATING AGENTS IN PATIENTS ON HEMODIALYSIS- CASE STUDY OF A BRAZILIAN DIALYSIS CENTER

    May 1, 2008, 00:00

  • PHP32 WHATS DRIVING PRESCRIPTION COPAYMENTS?

    May 1, 2008, 00:00

  • PDB71 EVALUATION OF ECONOMIC OUTCOMES. ADHERENCE, AND GLYCEMIC CONTROL FOR DIABETIC PATIENTS IN A PHARMACIST-RUN MEDICATION MANAGEMENT PROGRAM

    May 1, 2008, 00:00

  • PRS44 ANALYSIS OF THE COSTS RELATED TO SMOKING HABITS OF BENEFICIARIES OF A BRAZILIAN HEALTH PLAN, WITH THE PURPOSE TO DEFINE TREATMENT STRATEGIES TO REIMBURSE FIRST LINE MEDICATIONS

    May 1, 2008, 00:00

  • DU7 NATIONAL ESTIMATES AND DETERMINANTS OF DEPRESSION AND ANTIDEPRESSANTTREATMENT IN CANCER PATIENTS IN THE UNITED STATES, 2004-2005

    May 1, 2008, 00:00

  • PMH79 PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA- ANALYSIS OFTHE NATIONAL HOSPITAL DISCHARGE REGISTRY

    May 1, 2008, 00:00

  • PSY36 COMPLEMENTARY AND ALTERNATIVE MEDICINE AND HEALTH CARE UTILIZATION IN PATIENTS WITH NON-CANCER CHRONIC PAIN

    May 1, 2008, 00:00

  • PDB21 COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) IN THE CANADIAN PAYER SETTING- MODELING ANALYSIS USING AN OBSERVATIONAL STUDY

    May 1, 2008, 00:00

  • PCN30 COSTS RELATED TO ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN CANADA

    May 1, 2008, 00:00

  • CA1 ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS INTHE PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH-A CANADIAN PERSPECTIVE

    May 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158 (current)
  • 159
  • 160
  • »